桑加莫生物科学 SGMO 深 沪
已收盘 12-31 16:00:00 美东时间
0.42
-0.007
-1.71%
华盛通- 最 高0.43
- 今 开0.4273
- 成交量 493.98万股
- 最 低 0.406
- 昨 收 0.4273
- 总市值 1.27亿
- 52周最高 1.51
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 0.3846
- 委 比 -99.17%
- 总股本 3.02亿
- 历史最高 27.50
- 量 比 1.20
- 振 幅 5.62%
- 历史最低 0.2911
- 每 手 1
- 风险率 0.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sangamo Therapeutics Initiates Rolling Submission Of BLA To FDA Seeking Accelerated Approval Of Isaralgagene Civaparvovec, Or ST-920, Investigational Gene Therapy For Treatment Of Adults With Fabry Disease
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve
2025-12-18 21:12
Sangam Therapeutics shares are trading higher after the FDA granted Fast Track Designation to ST-503.
Sangam Therapeutics shares are trading higher after the FDA granted Fast Track ...
2025-12-02 21:51
Sangamo Therapeutics Biologics License Application Gets FDA's Acceptance For Isaralgagene Civaparvovec To Treat Fabry Disease
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request for a rolling submission and review of the Biologics
2025-11-21 21:08
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1
Barclays analyst Gena Wang downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and lowers the price target from $5 to $1.
2025-11-07 20:24
电话会总结 ｜ Sangamo(SGMO)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Sangamo业绩会实录，我需要指出一个重要问题： **财务信息披露不足** 本次业绩会实录中**缺乏详细的财务业绩数据**。会议主要聚焦于临床试验进展、监管事务和业务发展，而未提供传统的财务报表数据。 ## 1. 财务业绩：- **营收(Revenue)**：未披露具体营收数据 - **利润率(Profit Margin)**：未披露毛利率或净利润率数据 - **净利润(Net Income)**：未披露净利润或亏损数据 - **现金流(Cash Flow)**：未披露经营性现金流或自由现金流数据 ## 2. 财务指标变化：- **现金及现
2025-11-07 12:30
Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
Sangamo Therapeutics shares are trading lower after the company reported worse-...
2025-11-06 23:52
Sangamo Therapeutics Q3 EPS $(0.11) Misses $(0.01) Estimate, Sales $581.000K Miss $34.400M Estimate
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.01) by 1275 percent. This is a 375 percent decrease over earnings of $0.04 per share
2025-11-06 21:02
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
